10th International AIDS Society (IAS) Conference on HIV Science (IAS 2019)

HIV does not worsen COVID-19 outcomes

Elvira Manzano, 20200813104000

People living with HIV (PLWH) who are hospitalized for COVID-19 are not more likely to die than those without HIV despite having comorbidities associated with worse COVID-19 outcomes, a US study has shown.

Dolutegravir noninferior to low-dose efavirenz in HIV-1 suppression

Roshini Claire Anthony, 20190829140307

Dolutegravir demonstrated noninferiority to low-dose efavirenz in antiretroviral (ART)-naïve patients with HIV-1 infection in a resource-limited setting, according to the NAMSAL ANRS 12313* study presented at IAS 2019.

Tsepamo: Potential uptick in neural-tube defects with dolutegravir

Tsepamo: Potential uptick of neural-tube defects with dolutegravir-based ART

Pearl Toh, 20190822190000

Children born to women receiving dolutegravir-based antiretroviral therapy (ART) for HIV since conception have an uptick of neural-tube defects compared with those whose mothers took non-dolutegravir ART at conception, additional follow-up data from the Tsepamo surveillance study show.

Dolutegravir-emtricitabine + TAF/TDF combo ADVANCEs as potential HIV-1 treatment

Roshini Claire Anthony, 20190820140203

The combination of emtricitabine and dolutegravir with either a tenofovir alafenamide fumarate (TAF) or tenofovir disoproxil fumarate (TDF)-based regimen fared similarly to a TDF-emtricitabine-efavirenz regimen in reducing HIV-1 RNA levels, according to results of the phase III ADVANCE* study presented at IAS 2019.

Fostemsavir shows sustained virologic suppression in multidrug-resistant HIV

Fostemsavir shows sustained virologic suppression in resistant HIV

Pearl Toh, 20190819190000

The investigational first-in-class attachment inhibitor prodrug fostemsavir (FTR) continues to improve virologic and immunologic response from weeks 48 to 96 in patients with multidrug-resistant HIV-1 who had been heavily treated, according to the BRIGHTE* study presented at IAS 2019.

Two to TANGO: Dolutegravir-lamivudine combo safe, effective substitute for TAF regimen

Roshini Claire Anthony, 20190815140303

Individuals with HIV-1 who demonstrate virologic suppression on a tenofovir alafenamide fumarate (TAF)-based three- or four-drug regimen (TBR) could safely switch to a two-drug regimen comprising dolutegravir and lamivudine, according to results from the phase III TANGO* study presented at the recent International AIDS Society conference (IAS 2019).

Single-tablet combo regimen fares well in HIV treatment

Audrey Abella, 20190806100000

The guideline-recommended, single-tablet, fixed-dose regimen comprising bictegravir, emtricitabine, and tenofovir alafenamide (B/F/TAF) was noninferior to the dolutegravir and F/TAF (D/F/TAF) regimen in persons living with HIV (PLHIV), according to data presented at IAS 2019.

Monthly cabotegravir-rilpivirine favoured by PLHIV

Audrey Abella, 20190805100000

Persons living with HIV (PLHIV) who received monthly long-acting (LA) intramuscular formulations of the INSTI* cabotegravir and the NNRTI** rilpivirine reported higher levels of treatment satisfaction and treatment acceptance, and greater willingness to continue therapy as opposed to a daily oral antiretroviral therapy (ART) regimen, according to patient-reported outcomes of the ATLAS*** and FLAIR# trials presented at IAS 2019.